Tengs Tammy O, Lin Ting H
Health Priorities Research Group, School of Social Ecology, University of California, Irvine 92697-7075, USA.
Med Decis Making. 2002 Nov-Dec;22(6):475-81. doi: 10.1177/0272989X02238300.
The authors performed a meta-analysis to derive pooled utilities for HIV/AIDS and to assess the relative importance of study design characteristics in predicting utilities. Twenty-five articles were identified reporting 74 unique utilities elicited from 1956 respondents. The authors used a hierarchical linear model to perform the meta-analysis, with disease stage, elicitation method, respondent type, and the upper-bound and lower-bound labels for the utility scale as the independent variables. Disease stage (P = 0.016) and respondent type (P = 0.014) were significant predictors of utility. Elicitation method was of marginal significance (P = 0. 052). Bounds were not significant. Pooling utilities, the authors estimate a utility of 0.70 for AIDS, 0.82 for symptomatic HIV and 0.94 for asymptomatic HIV when the time tradeoff method is used to elicit utilities from patients and the scale ranges from death to perfect health. The pooled utilities reported here should be of great use to researchers performing cost-utility analyses of interventions for HIV/AIDS.
作者进行了一项荟萃分析，以得出针对艾滋病毒/艾滋病的合并效用值，并评估研究设计特征在预测效用方面的相对重要性。共识别出25篇文章，报告了从1956名受访者中得出的74个独特的效用值。作者使用分层线性模型进行荟萃分析，将疾病阶段、引出方法、受访者类型以及效用量表的上限和下限标签作为自变量。疾病阶段（P = 0.016）和受访者类型（P = 0.014）是效用的显著预测因素。引出方法具有边际显著性（P = 0.052）。边界不显著。通过合并效用值，作者估计，当使用时间权衡法从患者中引出效用值且量表范围从死亡到完美健康时，艾滋病的效用值为0.70，有症状艾滋病毒的效用值为0.82，无症状艾滋病毒的效用值为0.94。此处报告的合并效用值对于对艾滋病毒/艾滋病干预措施进行成本效用分析的研究人员应具有很大用处。
